triiodothyronine has been researched along with Basal Ganglia Diseases in 2 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, 93 chronic inpatients with schizophrenia were comprehensively investigated in order to examine the association of psychiatric and extrapyramidal symptoms with prolactin, thyroid hormones (free triiodothyronine (T₃), free thyroxine (T₄), thyroid stimulating hormone), cortisol and BDNF." | 7.78 | Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia. ( Hoaki, N; Hoaki, T; Ichioka, S; Matsushita, T; Terao, T, 2012) |
| "In this study, 93 chronic inpatients with schizophrenia were comprehensively investigated in order to examine the association of psychiatric and extrapyramidal symptoms with prolactin, thyroid hormones (free triiodothyronine (T₃), free thyroxine (T₄), thyroid stimulating hormone), cortisol and BDNF." | 3.78 | Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia. ( Hoaki, N; Hoaki, T; Ichioka, S; Matsushita, T; Terao, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichioka, S | 1 |
| Terao, T | 1 |
| Hoaki, N | 1 |
| Matsushita, T | 1 |
| Hoaki, T | 1 |
| Arii, J | 1 |
| Tanabe, Y | 1 |
| Makino, M | 1 |
| Sato, H | 1 |
| Kohno, Y | 1 |
2 other studies available for triiodothyronine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Brain-Derived Neurotro | 2012 |
Children with irreversible brain damage associated with hypothyroidism and multiple intracranial calcifications.
Topics: Basal Ganglia Diseases; Calcinosis; Cerebral Palsy; Child, Preschool; Female; Growth Disorders; Huma | 2002 |